UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Finance receivable interest income, including fees	$ 10,415	$ 8,679
Pharmaceutical development	236	198
Other	480	496
Total revenues	11,131	9,373
Costs and expenses:
Interest expense	80	145
Pharmaceutical manufacturing, research and development expense	1,901	1,548
Depreciation and amortization expense	704	1,682
General and administrative	3,160	2,885
Income from operations	5,286	3,113
Other (expense) income, net
Unrealized net (loss) gain on derivatives	(693)	283
Unrealized net (loss) gain on equity securities	(28)	932
Income before income tax expense	4,565	4,328
Income tax expense	1,087	939
Net income	$ 3,478	$ 3,389
Net income per share
Basic	$ 0.27	$ 0.26
Diluted	$ 0.27	$ 0.26
Weighted Average Shares
Basic	12,830,000	12,793,000
Diluted	12,888,000	12,810,000